• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cross-protection to new drifted influenza A(H3) viruses and prevalence of protective antibodies to seasonal influenza, during 2014 in Portugal

tetano

Editor, Senior Moderator
Vaccine. 2017 Mar 15. pii: S0264-410X(17)30213-X. doi: 10.1016/j.vaccine.2017.02.019. [Epub ahead of print]
[h=1]Cross-protection to new drifted influenza A(H3) viruses and prevalence of protective antibodies to seasonal influenza, during 2014 in Portugal.[/h] Guiomar R[SUP]1[/SUP], Pereira da Silva S[SUP]2[/SUP], Conde P[SUP]3[/SUP], Crist?v?o P[SUP]4[/SUP], Maia AC[SUP]5[/SUP], Pechirra P[SUP]6[/SUP], Rodrigues AP[SUP]7[/SUP], Nunes B[SUP]8[/SUP]; Portuguese Laboratory Network for the Diagnosis of Influenza Infection, Milho L[SUP]9[/SUP], Coelho AP[SUP]10[/SUP], Fernandes A[SUP]11[/SUP], Caseiro P[SUP]12[/SUP], Rodrigues F[SUP]13[/SUP], Correia L[SUP]14[/SUP], Pereira-Vaz J[SUP]15[/SUP], Almeida S[SUP]16[/SUP], Branquinho P[SUP]17[/SUP], C?rte-Real R[SUP]18[/SUP], Viseu R[SUP]19[/SUP], Peres MJ[SUP]20[/SUP], Sanches R[SUP]21[/SUP], Dantas F[SUP]21[/SUP], Freitas L[SUP]21[/SUP], Andrade G[SUP]22[/SUP], Maur?lio M[SUP]23[/SUP], Caldeira F[SUP]24[/SUP], Cabral Veloso R[SUP]25[/SUP], Mota-Vieira L[SUP]26[/SUP], Soares M[SUP]27[/SUP], Couto AR[SUP]28[/SUP], Bruges-Armas J[SUP]29[/SUP], Pinto RM[SUP]30[/SUP], Sobrinho Sim?es J[SUP]31[/SUP], Costa MD[SUP]32[/SUP], Guimar?es JT[SUP]33[/SUP], Martins L[SUP]34[/SUP], Cunha M[SUP]35[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]INTRODUCTION:[/h] Immune profile for influenza viruses is highly changeable over time. Serological studies can assess the prevalence of influenza, estimate the risk of infection, highlight asymptomatic infection rate and can also provide data on vaccine coverage. The aims of the study were to evaluate pre-existing cross-protection against influenza A(H3) drift viruses and to assess influenza immunity in the Portuguese population.
[h=4]MATERIALS AND METHODS:[/h] We developed a cross-sectional study based on a convenience sample of 626 sera collected during June 2014, covering all age groups, both gender and all administrative health regions of Portugal. Sera antibody titers for seasonal and new A(H3) drift influenza virus were evaluated by hemagglutination inhibition assay (HI). Seroprevalence to each seasonal influenza vaccine strain virus and to the new A(H3) drift circulating strain was estimated by age group, gender and region and compared with seasonal influenza-like illness (ILI) incidence rates before and after the study period.
[h=4]RESULTS:[/h] Our findings suggest that seroprevalences of influenza A(H3) (39.9%; 95% CI: 36.2-43.8) and A(H1)pdm09 (29.7%; 95% CI: 26.3-33.4) antibodies were higher than for influenza B, in line with high ILI incidence rates for A(H3) followed by A(H1)pdm09, during 2013/2014 season. Low pre-existing cross-protection against new A(H3) drift viruses were observed in A(H3) seropositive individuals (46%). Both against influenza A(H1)pdm09 and A(H3) seroprotection was highest in younger than 14-years old. Protective antibodies against influenza B were highest in those older than 65years old, especially for B/Yamagata lineage, 33.3% (95% CI: 25.7-41.9). Women showed a high seroprevalence to influenza, although without statistical significance, when compared to men. A significant decreasing trend in seroprotection from north to south regions of Portugal mainland was observed.
[h=4]CONCLUSIONS:[/h] Our results emphasize that low seroprotection increases the risk of influenza infection in the following winter season. Seroepidemiological studies can inform policy makers on the need for vaccination and additional preventive measures.
Copyright ? 2017 Elsevier Ltd. All rights reserved.


[h=4]KEYWORDS:[/h] Cross-protection; Influenza; Seroepidemiologic studies; Seroprevalence

PMID: 28318771 DOI: 10.1016/j.vaccine.2017.02.019
 
Back
Top Bottom